8-K Announcements
6Material company update
May 12, 2026·SEC
Material company update
Mar 11, 2026·SEC
Material company update
Dec 30, 2025·SEC
Verrica Pharmaceuticals Inc.(VRCA)Earnings, Financials & Key Ratios
VRCA•NASDAQ
Price updated Jun 19, 2026
AboutVerrica Pharmaceuticals Inc., a dermatology therapeutics company, develops and commercializes treatments for people with skin diseases in the United States. The company's lead product candidate includes VP-102 for the treatment of molluscum contagiosum; that has completed Phase II clinical trial for the treatment of external genital warts; and which is in Phase II clinical trial for treating common warts. It is also developing cantharidin-based product candidate, VP-103 for treating plantar warts. The company has a license and collaboration agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize LTX-315 for dermatological oncology indications. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.Show more
- Revenue$36M+370.2%
- EBITDA-$11M+82.7%
- Net Income-$18M+76.6%
- EPS (Diluted)-1.68+88.6%
- Gross Margin90.33%+41.6%
- EBITDA Margin-31.36%+96.3%
- Operating Margin-33.56%+96.1%
- Net Margin-50.27%+95.0%
- ROE-240.35%+84.5%
VRCA Key Insights
Verrica Pharmaceuticals Inc. (VRCA) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Strong 5Y profit CAGR of 17.0%
✗Weaknesses
- ✗Negative free cash flow
- ✗Shares diluted 100.0% in last year
- ✗Trading more than 30% below 52-week high
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when VRCA posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
VRCA Price & Volume
Verrica Pharmaceuticals Inc. (VRCA) stock price & volume — 10-year historical chart
Loading chart...
VRCA Growth Metrics
Verrica Pharmaceuticals Inc. (VRCA) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years57.93%
TTM417.63%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM72.99%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM87.03%
Return on Capital
10 Years-225.88%
5 Years-92.1%
3 Years-104.68%
Last Year-42.78%
VRCA Recent Earnings
Verrica Pharmaceuticals Inc. (VRCA) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 8/12 qtrs (67%)●Beat Revenue 9/12 qtrs (75%)
Q2 2026Latest
May 12, 2026Metric
Actual
Est
EPS
$0.41+30.5%
$0.59
Rev
$5M+11.3%
$5M
Q2 2026
Mar 11, 2026Metric
Actual
Est
EPS
$0.56-30.2%
$0.43
Rev
$5M+12.7%
$5M
Q4 2025
Nov 14, 2025Metric
Actual
Est
EPS
$0.13+111.4%
$1.14
Rev
$14M+217.3%
$5M
Q3 2025
Aug 12, 2025Metric
Actual
Est
EPS
$0.02+102.9%
$0.70
Rev
$13M+96.9%
$6M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 12, 2026 | $0.41vs $0.59+30.5% | $5Mvs $5M+11.3% |
| Q2 2026 | Mar 11, 2026 | $0.56vs $0.43-30.2% | $5Mvs $5M+12.7% |
| Q4 2025 | Nov 14, 2025 | $0.13vs $1.14+111.4% | $14Mvs $5M+217.3% |
| Q3 2025 | Aug 12, 2025 | $0.02vs $0.70+102.9% | $13Mvs $6M+96.9% |
Based on last 12 quarters of dataView full earnings history →
VRCA Peer Comparison
Verrica Pharmaceuticals Inc. (VRCA) competitors in Commercial Specialty Pharma — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 DERM | 171.19M | 6.22 | -13.23 | 10.2% | -14.82% | -35.57% | 0.00 | |
 PRGO | 1.42B | 10.25 | -1.00 | -2.75% | -43.5% | -50.65% | 1.35 | |
 NVCR | 1.62B | 14.28 | -11.70 | 8.28% | -25.66% | -50.82% | 0.85 | |
 SKIN | 85.9M | 0.66 | -4.14 | -10.02% | -2.03% | -9.41% | 6.20 | |
 GDRX | 922.03M | 2.66 | 31.18 | 0.57% | 3.74% | 4.75% | 0.10 | |
 ETON | 889.7M | 32.48 | -191.06 | 104.94% | -1.7% | -5.68% | 1.19 | |
 PHAT | 864.2M | 10.88 | -3.59 | 216.93% | -61.95% | |||
 AVDL | 2.1B | 21.64 | -42.43 | 5.05% | -0.11% | -0.33% | 0.02 |
Compare VRCA vs Peers
Verrica Pharmaceuticals Inc. (VRCA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
VRCA Income Statement
Verrica Pharmaceuticals Inc. (VRCA) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 0 | 0 | 0 | 0 | 12M | 9.03M | 5.12M | 7.57M | 35.58M | 37.16M |
Revenue Growth % | - | - | - | - | - | -24.73% | -43.27% | 47.66% | 370.22% | 417.63% |
Cost of Goods Sold | 0 | 20.29K | 257.2K | 229K | 472K | 725K | 746K | 2.74M | 3.44M | 3.89M |
COGS % of Revenue | - | - | - | - | 3.93% | 8.03% | 14.56% | 36.21% | 9.67% | - |
Gross Profit | 0▲ 0% | -20.29K▲ 0% | -257.2K▼ 1167.4% | -229K▲ 11.0% | 11.53M▲ 5134.1% | 8.31M▼ 27.9% | 4.38M▼ 47.3% | 4.83M▲ 10.2% | 32.14M▲ 565.9% | 33.27M▲ 0% |
Gross Margin % | - | - | - | - | 96.07% | 91.97% | 85.44% | 63.79% | 90.33% | 89.52% |
Gross Profit Growth % | - | - | -1167.36% | 10.96% | 5134.06% | -27.94% | -47.3% | 10.23% | 565.89% | - |
Operating Expenses | 4.46M | 21.88M | 29.82M | 39.95M | 42.44M | 29.6M | 70.14M | 70.75M | 44.08M | 46.79M |
OpEx % of Revenue | - | - | - | - | 353.63% | 327.76% | 1368.79% | 935.04% | 123.89% | - |
Selling, General & Admin | 727K | 9.05M | 14.39M | 24.51M | 26.98M | 17.41M | 47.3M | 58.82M | 35.22M | 36.36M |
SG&A % of Revenue | - | - | - | - | 224.83% | 192.7% | 923.2% | 777.45% | 99% | - |
Research & Development | 3.73M | 12.83M | 15.44M | 15.67M | 15.93M | 12.2M | 20.3M | 11.84M | 8.86M | 10.43M |
R&D % of Revenue | - | - | - | - | 132.74% | 135.05% | 396.08% | 156.49% | 24.89% | - |
Other Operating Expenses | 0 | -1K | 0 | -229K | -472K | 0 | 2.54M | 83K | 0 | 0 |
Operating Income | -4.46M▲ 0% | -21.88M▼ 390.9% | -30.08M▼ 37.5% | -40.18M▼ 33.6% | -30.91M▲ 23.1% | -21.3M▲ 31.1% | -65.76M▼ 208.8% | -65.92M▼ 0.2% | -11.94M▲ 81.9% | -13.52M▲ 0% |
Operating Margin % | - | - | - | - | -257.57% | -235.78% | -1283.35% | -871.25% | -33.56% | -36.39% |
Operating Income Growth % | -132.98% | -390.87% | -37.49% | -33.58% | 23.08% | 31.1% | -208.79% | -0.24% | 81.89% | - |
EBITDA | 0 | -21.86M | -29.82M | -39.95M | -30.44M | -20.58M | -64.92M | -64.65M | -11.16M | -12.76M |
EBITDA Margin % | - | - | - | - | -253.63% | -227.83% | -1267.04% | -854.48% | -31.36% | -34.33% |
EBITDA Growth % | - | - | -36.44% | -33.96% | 23.82% | 32.39% | -215.5% | 0.42% | 82.74% | 76.51% |
D&A (Non-Cash Add-back) | 4.46M | 20.29K | 257.2K | 229K | 472K | 718K | 836K | 1.27M | 781K | 767K |
EBIT | -4.46M | -20.65M | -28.21M | -39.66M | -30.79M | -22.32M | -63.03M | -67.17M | -10.14M | -12.32M |
Net Interest Income | 0 | 0 | 1.88M | -2.51M | -4.17M | -1.7M | -1.22M | -8M | -6.81M | -4.91M |
Interest Income | 0 | 1.23M | 1.88M | 521K | 123K | 476K | 2.74M | 1.42M | 929K | 793K |
Interest Expense | 2K | 0 | 0 | 3.03M | 4.29M | 2.17M | 3.96M | 9.41M | 7.74M | 5.7M |
Other Income/Expense | -2K | 1.23M | 1.87M | -2.51M | -4.17M | -3.19M | -1.24M | -10.66M | -5.95M | -4.3M |
Pretax Income | -4.46M▲ 0% | -20.65M▼ 363.1% | -28.21M▼ 36.6% | -42.69M▼ 51.4% | -35.08M▲ 17.8% | -24.49M▲ 30.2% | -67M▼ 173.6% | -76.58M▼ 14.3% | -17.89M▲ 76.6% | -17.83M▲ 0% |
Pretax Margin % | - | - | - | - | -292.33% | -271.11% | -1307.47% | -1012.15% | -50.27% | -47.97% |
Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Net Income | -4.46M▲ 0% | -20.65M▼ 363.1% | -28.21M▼ 36.6% | -45.5M▼ 61.3% | -35.08M▲ 22.9% | -24.49M▲ 30.2% | -67M▼ 173.6% | -76.58M▼ 14.3% | -17.89M▲ 76.6% | -17.83M▲ 0% |
Net Margin % | - | - | - | - | -292.33% | -271.11% | -1307.47% | -1012.15% | -50.27% | -47.97% |
Net Income Growth % | -133.09% | -363.06% | -36.61% | -61.3% | 22.9% | 30.2% | -173.59% | -14.31% | 76.64% | 72.99% |
Net Income (Continuing) | -4.46M | -20.65M | -28.21M | -42.69M | -35.08M | -24.49M | -67M | -76.58M | -17.89M | -17.83M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -3.80▲ 0% | -8.31▼ 118.8% | -11.33▼ 36.3% | -17.08▼ 50.8% | -12.97▲ 24.1% | -7.17▲ 44.7% | -14.78▼ 106.1% | -14.78▲ 0.0% | -1.68▲ 88.6% | -1.67▲ 0% |
EPS Growth % | -410.11% | -118.81% | -36.34% | -50.75% | 24.06% | 44.72% | -106.14% | 0% | 88.63% | 87.03% |
EPS (Basic) | -3.80 | -8.31 | -11.33 | -17.08 | -12.97 | -7.17 | -14.78 | -14.78 | -1.68 | - |
Diluted Shares Outstanding | 2.57M | 2.49M | 2.49M | 2.5M | 2.7M | 3.42M | 4.53M | 5.18M | 10.65M | 10.65M |
Basic Shares Outstanding | 2.57M | 2.49M | 2.49M | 2.5M | 2.7M | 3.42M | 4.53M | 5.18M | 10.65M | 10.65M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
VRCA Balance Sheet
Verrica Pharmaceuticals Inc. (VRCA) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 9.08M | 91.15M | 64.98M | 67.65M | 74.33M | 39.12M | 77.53M | 51.18M | 42.54M | 32.76M |
Cash & Short-Term Investments | 8.66M | 89.81M | 62.02M | 65.47M | 70.35M | 34.27M | 69.55M | 46.33M | 30.15M | 20.6M |
Cash Only | 8.66M | 10.27M | 9.24M | 10.69M | 15.75M | 34.27M | 69.55M | 46.33M | 30.15M | 20.6M |
Short-Term Investments | 0 | 79.54M | 52.78M | 54.78M | 54.6M | 0 | 0 | 0 | 0 | 0 |
Accounts Receivable | 0 | 0 | 0 | 0 | 0 | 487K | 4.42M | 77K | 5.4M | 7.81M |
Days Sales Outstanding | - | - | - | - | - | 19.68 | 314.57 | 3.71 | 55.37 | 93.09 |
Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 1.02M | 2.46M | 2.24M | 1.97M |
Days Inventory Outstanding | - | - | - | - | - | - | 500.04 | 328.1 | 237.18 | 211.8 |
Other Current Assets | 0 | 0 | 0 | 0 | 0 | 4.36M | 2.54M | 2.31M | 4.76M | 2.37M |
Total Non-Current Assets | 0 | 754K | 3.44M | 6.5M | 5.8M | 5.61M | 4.07M | 2.96M | 4.59M | 6.03M |
Property, Plant & Equipment | 0 | 255K | 2.2M | 4.94M | 5.5M | 5.33M | 3.62M | 2.58M | 1.86M | 1.66M |
Fixed Asset Turnover | - | - | - | - | 2.18x | 1.69x | 1.42x | 2.93x | 19.11x | 20.18x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 264K |
Other Non-Current Assets | 0 | 499K | 1.24M | 1.57M | 295K | 276K | 452K | 376K | 2.73M | 4.1M |
Total Assets | 9.08M▲ 0% | 91.91M▲ 911.8% | 68.42M▼ 25.6% | 74.15M▲ 8.4% | 80.13M▲ 8.1% | 44.72M▼ 44.2% | 81.6M▲ 82.5% | 54.13M▼ 33.7% | 47.13M▼ 12.9% | 38.79M▲ 0% |
Asset Turnover | - | - | - | - | 0.15x | 0.20x | 0.06x | 0.14x | 0.75x | 0.90x |
Asset Growth % | 1569.67% | 911.85% | -25.55% | 8.37% | 8.05% | -44.19% | 82.46% | -33.66% | -12.94% | -21.59% |
Total Current Liabilities | 616K | 2.48M | 3.35M | 39.48M | 46.05M | 3.46M | 17.02M | 29.01M | 16.44M | 16.22M |
Accounts Payable | 167K | 960K | 1.19M | 348K | 845K | 507K | 2.46M | 1.9M | 2.07M | 2.19M |
Days Payables Outstanding | - | 17.27K | 1.68K | 554.67 | 653.44 | 255.25 | 1.21K | 252.57 | 219.78 | 191.52 |
Short-Term Debt | 0 | 0 | 0 | 35.31M | 41.69M | 0 | 0 | 12.94M | 746K | 744K |
Deferred Revenue (Current) | 0 | 0 | 0 | 500K | 0 | 0 | 0 | 0 | 782K | 3.86M |
Other Current Liabilities | 49K | 1.26M | 1.2M | 1.34M | 1.67M | 1.4M | 9.04M | 11.59M | 12.84M | 11.39M |
Current Ratio | 14.75x | 36.80x | 19.39x | 1.71x | 1.61x | 11.31x | 4.55x | 1.76x | 2.59x | 2.02x |
Quick Ratio | 14.75x | 36.80x | 19.39x | 1.71x | 1.61x | 11.31x | 4.49x | 1.68x | 2.45x | 1.90x |
Cash Conversion Cycle | - | - | - | - | - | - | -390.97 | 79.25 | 72.77 | 113.36 |
Total Non-Current Liabilities | 15.51M | 0 | 58K | 1.69M | 1.47M | 1.23M | 44.81M | 34.98M | 5.95M | 6.51M |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 42.87M | 30.98M | 0 | 0 |
Capital Lease Obligations | 0 | 0 | 58K | 1.69M | 1.47M | 1.23M | 1.94M | 1.35M | 885K | 3.54M |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 15.51M | 0 | 0 | 0 | 0 | 0 | 0 | 2.65M | 5.07M | 5.81M |
Total Liabilities | 16.12M | 2.48M | 3.41M | 41.17M | 47.52M | 4.69M | 61.83M | 63.99M | 22.39M | 22.73M |
Total Debt | 0 | 0 | 188K | 37.21M | 43.41M | 1.53M | 45.51M | 45.94M | 1.63M | 1.44M |
Net Debt | -8.66M | -10.27M | -9.05M | 26.52M | 27.66M | -32.75M | -24.04M | -390K | -28.52M | -19.16M |
Debt / Equity | - | - | 0.00x | 1.13x | 1.33x | 0.04x | 2.30x | - | 0.07x | 0.09x |
Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.11x |
Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | 1.50x |
Interest Coverage | -2228.50x | - | - | -13.08x | -7.17x | -10.27x | -15.91x | -7.14x | -1.31x | -2.16x |
Total Equity | -7.04M▲ 0% | 89.43M▲ 1370.1% | 65.02M▼ 27.3% | 32.99M▼ 49.3% | 32.6M▼ 1.2% | 40.03M▲ 22.8% | 19.76M▼ 50.6% | -9.86M▼ 149.9% | 24.74M▲ 350.9% | 16.05M▲ 0% |
Equity Growth % | -164.3% | 1370.12% | -27.3% | -49.26% | -1.16% | 22.78% | -50.63% | -149.89% | 350.94% | 555.87% |
Book Value per Share | -2.74 | 35.98 | 26.11 | 13.20 | 12.06 | 11.72 | 4.36 | -1.90 | 2.32 | 1.51 |
Total Shareholders' Equity | -7.04M | 89.43M | 65.02M | 32.99M | 32.6M | 40.03M | 19.76M | -9.86M | 24.74M | 16.05M |
Common Stock | 0 | 3K | 3K | 3K | 3K | 4K | 4K | 9K | 2K | 2K |
Retained Earnings | -12.44M | -33.08M | -61.19M | -103.89M | -138.97M | -163.45M | -230.45M | -307.03M | -324.91M | -334.6M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | 0 | -17K | 20K | 1K | -29K | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
VRCA Cash Flow Statement
Verrica Pharmaceuticals Inc. (VRCA) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -4.58M | -17.87M | -27.41M | -30.21M | -27.58M | -18.65M | -38.58M | -60.93M | -17.63M | -14.11M |
Operating CF Margin % | - | - | - | - | -229.85% | -206.49% | -752.87% | -805.27% | -49.55% | - |
Operating CF Growth % | -184.48% | -290.01% | -53.34% | -10.21% | 8.69% | 32.38% | -106.85% | -57.94% | 71.07% | 350.91% |
Net Income | -4.46M | -20.65M | -28.21M | -42.69M | -35.08M | -24.49M | -67M | -76.58M | -17.89M | -17.83M |
Depreciation & Amortization | 0 | 20K | 257.2K | 229K | 472K | 718K | 836K | 1.27M | 429K | 670K |
Stock-Based Compensation | 82K | 2.25M | 0 | 9.82M | 6.05M | 4.99M | 14.38M | 7.16M | 3.32M | 2.29M |
Deferred Taxes | 0 | 0 | 0 | 0 | 66K | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 18K | -435K | 2.27M | 802K | 1.44M | 1.93M | 3.35M | 5.19M | 2.76M | 4.44M |
Working Capital Changes | -206K | 938K | -1.73M | 1.64M | -535K | -1.8M | 9.86M | 2.03M | -6.25M | -3.69M |
Change in Receivables | 0 | 0 | 0 | 0 | 0 | -487K | -3.93M | 4.34M | -5.32M | -2.16M |
Change in Inventory | 0 | 0 | 0 | 0 | 0 | 487K | 0 | 0 | 0 | 480K |
Change in Payables | 64K | 793K | 225K | -838K | 497K | -338K | 2.2M | -568K | 176K | 750K |
Cash from Investing | 0 | -79.89M | 25.95M | -3.58M | -998K | 54.04M | -362K | -19K | 0 | 0 |
Capital Expenditures | 0 | -774K | -682K | -1.47M | -883K | -302K | -362K | -27K | 0 | 0 |
CapEx % of Revenue | - | - | - | - | 7.36% | 3.34% | 7.06% | 0.36% | - | 0% |
Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | 0 | -499K | -1.22M | -221K | -201K | -180K | 0 | 8K | 0 | 0 |
Cash from Financing | 12.72M | 99.38M | 423K | 35.23M | 33.65M | -16.87M | 74.21M | 37.73M | 1.45M | 5.38M |
Debt Issued (Net) | 0 | 0 | 0 | 34.37M | 4.97M | -43.75M | 44.08M | -2.06M | -48.2M | -44.26M |
Equity Issued (Net) | 13M | 99.38M | 423K | 453K | 28.12M | 26.9M | 30.3M | 39.64M | 50.07M | 50.06M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | -281K | 0 | 0 | 410K | 558K | -17K | -169K | 155K | -420K | -420K |
Net Change in Cash | 8.14M▲ 0% | 1.61M▼ 80.2% | -1.03M▼ 164.1% | 1.45M▲ 240.3% | 5.07M▲ 250.6% | 18.52M▲ 265.6% | 35.27M▲ 90.5% | -23.22M▼ 165.8% | -16.18M▲ 30.3% | -8.99M▲ 0% |
Free Cash Flow | -4.58M▲ 0% | -18.65M▼ 306.9% | -28.09M▼ 50.6% | -31.68M▼ 12.8% | -28.46M▲ 10.1% | -18.95M▲ 33.4% | -38.94M▼ 105.5% | -60.95M▼ 56.5% | -17.63M▲ 71.1% | -14.11M▲ 0% |
FCF Margin % | - | - | - | - | -237.21% | -209.83% | -759.93% | -805.63% | -49.55% | -37.98% |
FCF Growth % | -184.48% | -306.89% | -50.63% | -12.77% | 10.14% | 33.42% | -105.46% | -56.54% | 71.08% | 73.71% |
FCF per Share | -1.78 | -7.50 | -11.28 | -12.67 | -10.53 | -5.55 | -8.59 | -11.77 | -1.65 | -1.32 |
FCF Conversion (FCF/Net Income) | 1.03x | 0.87x | 0.97x | 0.66x | 0.79x | 0.76x | 0.58x | 0.80x | 0.99x | 0.79x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1.38M |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
VRCA Key Ratios
Verrica Pharmaceuticals Inc. (VRCA) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | - | -50.12% | -36.53% | -92.85% | -106.97% | -67.42% | -224.08% | -1546.58% | -240.35% | -1136.5% |
Return on Invested Capital (ROIC) | - | -51.72% | -33.39% | -52.2% | -38.71% | -47.29% | -3274.85% | - | - | 1243.01% |
Gross Margin | - | - | - | - | 96.07% | 91.97% | 85.44% | 63.79% | 90.33% | 89.52% |
Net Margin | - | - | - | - | -292.33% | -271.11% | -1307.47% | -1012.15% | -50.27% | -47.97% |
Debt / Equity | - | - | 0.00x | 1.13x | 1.33x | 0.04x | 2.30x | - | 0.07x | 0.09x |
Interest Coverage | -2228.50x | - | - | -13.08x | -7.17x | -10.27x | -15.91x | -7.14x | -1.31x | -2.16x |
FCF Conversion | 1.03x | 0.87x | 0.97x | 0.66x | 0.79x | 0.76x | 0.58x | 0.80x | 0.99x | 0.79x |
Revenue Growth | - | - | - | - | - | -24.73% | -43.27% | 47.66% | 370.22% | 417.63% |
Related:VRCA Dividend History·VRCA Revenue History·VRCA Price History·VRCA P/E History·VRCA Financial Ratios·VRCA Institutional Holders
VRCA SEC Filings & Documents
Verrica Pharmaceuticals Inc. (VRCA) SEC filings — annual & quarterly reports (10-K, 10-Q)
VRCA Frequently Asked Questions
Verrica Pharmaceuticals Inc. (VRCA) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Verrica Pharmaceuticals Inc. (VRCA) reported $37.2M in revenue for fiscal year 2025.
Verrica Pharmaceuticals Inc. (VRCA) grew revenue by 370.2% over the past year. This is strong growth.
Verrica Pharmaceuticals Inc. (VRCA) reported a net loss of $17.8M for fiscal year 2025.
Dividend & Returns
Verrica Pharmaceuticals Inc. (VRCA) has a return on equity (ROE) of -240.4%. Negative ROE indicates the company is unprofitable.
Verrica Pharmaceuticals Inc. (VRCA) had negative free cash flow of $14.1M in fiscal year 2025, likely due to heavy capital investments.